MT Newswires
Oppenheimer Adjusts Price Target on BridgeBio Pharma to $81 From $83, Maintains Outperform Rating
📈
AI Sentiment
Highly Positive
8/10
- Home
- BBIO
as of 02-25-2026 3:46pm EST
$65.88
$2.43
-3.56%
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 15.3B | IPO Year: | 2019 |
| Target Price: | $79.91 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.78 | EPS Growth: | -31.25 |
| 52 Week Low/High: | $28.33 - $84.94 | Next Earning Date: | 05-22-2026 |
| Revenue: | $502,076,000 | Revenue Growth: | 126.26% |
| Revenue Growth (this year): | 85.55% | Revenue Growth (next year): | 71.10% |
| P/E Ratio: | -24.48 | Index: | N/A |
| Free Cash Flow: | -447007000.0 | FCF Growth: | N/A |
AI-Powered BBIO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 79.25%
79.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
Kumar Neil
Sell
Chief Executive Officer
BBIO Feb 19, 2026
Avg Cost/Share
$71.97
Shares
28,053
Total Value
$2,002,717.48
Owned After
235,053
Scott Randal W.
Sell
Director
BBIO Feb 17, 2026
Avg Cost/Share
$75.28
Shares
10,000
Total Value
$754,556.60
Owned After
11,589
Trimarchi Thomas
Sell
President and CFO
BBIO Feb 17, 2026
Avg Cost/Share
$75.04
Shares
13,600
Total Value
$1,016,147.12
Owned After
336,585
Apuli Maricel
Sell
Chief Accounting Officer
BBIO Feb 17, 2026
Avg Cost/Share
$74.31
Shares
510
Total Value
$37,898.10
Owned After
123,945
SEC Form 4
Kumar Neil
Sell
Chief Executive Officer
BBIO Feb 11, 2026
Avg Cost/Share
$72.01
Shares
40,000
Total Value
$2,871,086.55
Owned After
235,053
Kumar Neil
Sell
Chief Executive Officer
BBIO Feb 10, 2026
Avg Cost/Share
$72.04
Shares
40,000
Total Value
$2,877,579.68
Owned After
235,053
Kumar Neil
Sell
Chief Executive Officer
BBIO Jan 9, 2026
Avg Cost/Share
$77.00
Shares
40,000
Total Value
$3,084,313.33
Owned After
235,053
Kumar Neil
Sell
Chief Executive Officer
BBIO Jan 8, 2026
Avg Cost/Share
$74.40
Shares
40,000
Total Value
$2,958,854.90
Owned After
235,053
Kumar Neil
Sell
Chief Executive Officer
BBIO Dec 15, 2025
Avg Cost/Share
$74.92
Shares
30,011
Total Value
$2,239,902.15
Owned After
235,053
Apuli Maricel
Sell
Chief Accounting Officer
BBIO Dec 8, 2025
Avg Cost/Share
$74.26
Shares
2,000
Total Value
$148,520.00
Owned After
123,945
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kumar Neil | BBIO | Chief Executive Officer | Feb 19, 2026 | Sell | $71.97 | 28,053 | $2,002,717.48 | 235,053 | |
| Scott Randal W. | BBIO | Director | Feb 17, 2026 | Sell | $75.28 | 10,000 | $754,556.60 | 11,589 | |
| Trimarchi Thomas | BBIO | President and CFO | Feb 17, 2026 | Sell | $75.04 | 13,600 | $1,016,147.12 | 336,585 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | Feb 17, 2026 | Sell | $74.31 | 510 | $37,898.10 | 123,945 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 11, 2026 | Sell | $72.01 | 40,000 | $2,871,086.55 | 235,053 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 10, 2026 | Sell | $72.04 | 40,000 | $2,877,579.68 | 235,053 | |
| Kumar Neil | BBIO | Chief Executive Officer | Jan 9, 2026 | Sell | $77.00 | 40,000 | $3,084,313.33 | 235,053 | |
| Kumar Neil | BBIO | Chief Executive Officer | Jan 8, 2026 | Sell | $74.40 | 40,000 | $2,958,854.90 | 235,053 | |
| Kumar Neil | BBIO | Chief Executive Officer | Dec 15, 2025 | Sell | $74.92 | 30,011 | $2,239,902.15 | 235,053 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | Dec 8, 2025 | Sell | $74.26 | 2,000 | $148,520.00 | 123,945 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
Morgan Stanley Lifts Price Target on BridgeBio Pharma to $98 From $96, Keeps Overweight Rating
📈
AI Sentiment
Highly Positive
8/10
GuruFocus.com
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
📊
AI Sentiment
Positive
7/10
Zacks
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates
📉
AI Sentiment
Negative
3/10
Motley Fool
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
📈
AI Sentiment
Highly Positive
10/10
MarketBeat
BridgeBio Pharma Q4 Earnings Call Highlights
Associated Press Finance
BridgeBio Pharma: Q4 Earnings Snapshot
Compare BBIO vs Leading Stocks
See how BBIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.